Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Barrett Esophagus 15Esophageal Neoplasms 10Colorectal Neoplasms 10Rectal Neoplasms 7Adenocarcinoma Of Esophagus 7Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Gastroesophageal Reflux 4Polyps 3Pathologic Complete Response 3Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Carcinoma 3Precancerous Conditions 2Hyperplasia 2Fistula 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenomatous Polyposis Coli 2Adenocarcinoma 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Signs and Symptoms 1Sarcoma 1

Interventions

Celecoxib 7Biopsy 5Sulindac 4Specimen Handling 3Eflornithine 3Curcumin 3guselkumab 2Ursodeoxycholic Acid 2Surveys and Questionnaires 2Sirolimus 2Sigmoidoscopy 2Gastroscopy 2Erythromycin 2Erlotinib Hydrochloride 2Endoscopy, Gastrointestinal 2Endoscopy, Digestive System 2Endoscopy 2Colonoscopy 2trifluridine tipiracil drug combination 1rofecoxib 1obeticholic acid 1Thiamine 1Surgical Procedures, Operative 1Suppositories 1Probiotics 1Polymorphism, Single-Stranded Conformational 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Endoscopy × Clear all
NCT00510692 2014-08-22

Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

S.L.A. Pharma AG

Phase 2/3 Completed
58 enrolled 12 charts
Gastrointestinal

Hyperplasia, Adenomatous Polyposis Coli, Polyps

NCT02162173 2014-06-12

PIVI

King Chulalongkorn Memorial Hospital

Phase NA Completed
26 enrolled
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡